about bic conference

The BIC International Conference is addressed to a relatively narrow selection of medical specialties since it is meant to feature only the most novel advances of basic science and clinical research in haemophilia, rare inherited coagulation disorders, von Willebrand factor and von Willebrand disease, gene therapy, the thrombotic microangiopathies and, of course, factor VIII inhibitors.

hemophilia

At the upcoming Conference, clinical and translational science will be again discussed from different angles. The most distinguished experts in the field will present their very latest data and offer their wisdom and insight into the current science developments.

Sponsor companies will have the opportunity of presenting their latest findings and innovations during their satellite symposia and discuss further developments with a highly competent audience.

ORGANIZED BY

The Scientific Committee and the Organizational Secretariat are already working on the next edition of this Conference, which will be held in Italy in 2021.
TO BE INFORMED ABOUT THE PROGRAMME AND LOCATION, PLEASE SIGN UP FOR THE FREE ALERT SERVICE

I authorize the use of my data for purposes related exclusively to this event. POLICY
I authorize the use of my personal data by SMC Media srl for information on future events / initiatives. POLICY

The Joint meeting of the 10th BIC and the 3rd Inhibitors in Hemophilia International Conference was held in Italy from 6-8 September 2019.
We are glad that the Conference was highly appreciated, as you can read in the customer satisfaction report available HERE.

ATTENDANTS

FULL DAYS OF PROGRAMME

SPONSORED SYMPOSIA/LECTURES

ACCEPTED ABSTRACTS

SPONSORS

WHAT WAS YOUR MAIN REASON FOR ATTENDING THE CONFERENCE?

  • To learn about recent clinical & therapies 66,1% 66,1%
  • To learn about recent research 67,7% 67,7%
  • To present a poster 19,4% 19,4%
  • To meet people and network 58,1% 58,1%
  • To present the abstract (oral communication) 1,6% 1,6%

THE CONFERENCE PROGRAMME WAS MUCH APPRECIATED FOR ITS HIGHLY INNOVATIVE SCIENTIFIC CONTENT

  • EXCELLENT 55% VERY GOOD 37%